Fig. 5

ROR1/CD3 inhibited tumor growth in TNBC xenograft mouse model. (A) The schematic diagram for the in vivo efficacy study (left panel). Administration of 1 mpk ROR1/CD3 antibody induced significantly tumor growth of NOG mice bearing MDA-MB-231 compared with mice treated with control IgG (right panel). N = 8 mice for each group. Two-way ANOVA was performed for data analysis. (B) No body weight loss was observed within mice treated with ROR1/CD3 antibody. (C, D) ROR1/CD3 suppressed the tumor growth of HCC1937 model on NOG mice. N = 8 mice for each group. Two-way ANOVA was performed for data analysis (C). No significant body weight loss was observed with the administration of ROR1/CD3 molecule (D). ROR1/CD3 engaged tumor-infiltrating T cells. Mice were treated with 1 mpk ROR1/CD3 after 20 days’ of tumor implantation. At day 27, tumors were isolated and analyzed for T cell activation and infiltration by flow cytometry. The percentage of CD4⁺, CD8⁺ T cells in tumors (E), the ratio of CD4⁺ or CD8⁺ in CD45⁺ T cell populations (F), granzyme B⁺ positive CD4⁺/CD8⁺ in CD4⁺ or CD8⁺ T cell (G), the ratio of CD4⁺ or CD8⁺ T cells in CD45⁺ population of the spleen (H) was determined. S student’s t test was performed for data analysis